Lactate Dehydrogenase B Is Associated with the Response to Neoadjuvant Chemotherapy in Oral Squamous Cell Carcinoma
文献类型：期刊论文
| 作者 | Sun, Wenyi1; Zhang, Xiaomin2; Ding, Xu2; Li, Huaiqi2; Geng, Meiyu1 ; Xie, Zuoquan1; Wu, Heming2; Huang, Min1
|
| 刊名 | PLOS ONE
 |
| 出版日期 | 2015-05-14 |
| 卷号 | 10期号:5 |
| ISSN号 | 1932-6203 |
| DOI | 10.1371/journal.pone.0125976 |
| 文献子类 | Article |
| 英文摘要 | Oral squamous cell carcinoma (OSCC) comprises a subset of head and neck squamous cell carcinoma (HNSCC) with poor therapeutic outcomes and high glycolytic dependency. Neoadjuvant chemotherapy regimens of docetaxel, cisplatin and 5-fluorouracil (TPF) are currently accepted as standard regimens for HNSCC patients with a high risk of distant metastatic spread. However, the antitumor outcomes of TPF neoadjuvant chemotherapy in HNSCC remain controversial. This study investigated the role of lactate dehydrogenase B (LDHB), a key glycolytic enzyme catalyzing the inter-conversion between pyruvate and lactate, in determining chemotherapy response and prognosis in OSCC patients. We discovered that a high protein level of LDHB in OSCC patients was associated with a poor response to TPF regimen chemotherapy as well as poor overall survival and disease-free survival. Our in-depth study revealed that high LDHB expression conferred resistance to taxol but not 5-fluorouracil or cisplatin. LDHB deletion sensitized OSCC cell lines to taxol, whereas the introduction of LDHB decreased sensitivity to taxol treatment. Taxol induced a pronounced impact on LDHB-downregulated OSCC cells in terms of apoptosis, G2/Mphase cell cycle arrest and energy metabolism. In conclusion, our study highlighted the critical role of LDHB in OSCC and proposed that LDHB could be used as a biomarker for the stratification of patients for TPF neoadjuvant chemotherapy and the determination of prognosis in OSCC patients. |
| WOS关键词 | INDUCIBLE FACTOR-I ; CANCER-CELLS ; NECK-CANCER ; INDUCTION CHEMOTHERAPY ; BREAST-CANCER ; TYROSINE PHOSPHORYLATION ; POOR-PROGNOSIS ; PHASE-III ; HEAD ; TAXOL |
| 资助项目 | National Natural Science Foundation of China[81222049] ; National Natural Science Foundation of China[81202549] ; National Science and Technology Major Project of the Ministry of Science and Technology of China[2012ZX09301001-004] ; National Science and Technology Major Project of the Ministry of Science and Technology of China[2012ZX09301001-007] ; Pujiang Scholar Program Grant by the Shanghai Metropolitan Government[12PJ1410400] |
| WOS研究方向 | Science & Technology - Other Topics |
| 语种 | 英语 |
| WOS记录号 | WOS:000354545600034 |
| 出版者 | PUBLIC LIBRARY SCIENCE |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/276529]  |
| 专题 | 药理学第一研究室 中科院受体结构与功能重点实验室 新药研究国家重点实验室 |
| 通讯作者 | Xie, Zuoquan |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, Div Antitumor Pharmacol, State Key Lab Drug Res, Shanghai 200031, Peoples R China; 2.Nanjing Med Univ, Affiliated Hosp Stomatol, Dept Oral & Maxillofacial Surg, Jiangsu Key Lab Oral Dis, Nanjing, Jiangsu, Peoples R China |
| 推荐引用方式 GB/T 7714 | Sun, Wenyi,Zhang, Xiaomin,Ding, Xu,et al. Lactate Dehydrogenase B Is Associated with the Response to Neoadjuvant Chemotherapy in Oral Squamous Cell Carcinoma[J]. PLOS ONE,2015,10(5). |
| APA | Sun, Wenyi.,Zhang, Xiaomin.,Ding, Xu.,Li, Huaiqi.,Geng, Meiyu.,...&Huang, Min.(2015).Lactate Dehydrogenase B Is Associated with the Response to Neoadjuvant Chemotherapy in Oral Squamous Cell Carcinoma.PLOS ONE,10(5). |
| MLA | Sun, Wenyi,et al."Lactate Dehydrogenase B Is Associated with the Response to Neoadjuvant Chemotherapy in Oral Squamous Cell Carcinoma".PLOS ONE 10.5(2015). |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。